February 5, 2026 — Leads & Copy — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced the filing of a preliminary prospectus supplement related to a proposed public offering of its common shares. The company has also applied to list its common shares on the Nasdaq Global Market under the ticker “MSLE.”
Trading on the Nasdaq is expected to begin after the pricing of the offering. The supplement was filed with securities regulatory authorities in British Columbia, Alberta, and Ontario, as well as with the U.S. Securities and Exchange Commission (SEC) as part of a registration statement on Form F-10.
Satellos intends to use the net proceeds from the offering to fund ongoing research and development activities, working capital, and general corporate purposes. This includes advancing the development of SAT-3247 through clinical trials and investing in other discovery-stage or pre-clinical development programs.
The company also expects to grant the underwriters an option to purchase up to an additional 15% of the common shares offered. The final terms of the offering will be determined at the time of pricing. There is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The closing of the offering will be subject to customary closing conditions, including approvals from the Toronto Stock Exchange and Nasdaq.
Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are acting as joint-book running managers for the offering. Bloom Burton is acting as co-manager.
The registration statement relating to the common shares has been filed with the SEC and automatically became effective upon filing. The supplement and accompanying base prospectus contain detailed information about the offering and are accessible on SEDAR+ at www.sedar.com and on EDGAR at www.sec.gov. Copies of the supplement and base prospectus may also be obtained from the Company by telephone at (647) 660-1780 or by email at ir@satellos.com, or from Leerink Partners, Guggenheim Securities, or Oppenheimer & Co.
Prospective investors should read the supplement and accompanying base prospectus and the other documents the Company has filed before making an investment decision. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC and on SEDAR+.
No regulatory authority has approved or disapproved the contents of this news release, which does not constitute an offer to sell or the solicitation of an offer to buy these securities in any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws.
Satellos Bioscience Inc. is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Its lead drug candidate, SAT-3247, is designed to address deficits in muscle repair and regeneration and is currently in clinical development as a potential disease-modifying treatment for DMD. The company is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit.
Source: Satellos Bioscience Inc.
